Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Amicus Therapeutics (FOLD) over the last 13 years, with Q3 2025 value amounting to $171.2 million.

  • Amicus Therapeutics' Accumulated Expenses rose 2574.94% to $171.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.2 million, marking a year-over-year increase of 2574.94%. This contributed to the annual value of $127.3 million for FY2024, which is 1174.74% down from last year.
  • Latest data reveals that Amicus Therapeutics reported Accumulated Expenses of $171.2 million as of Q3 2025, which was up 2574.94% from $145.1 million recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Accumulated Expenses peaked at $171.2 million during Q3 2025, and registered a low of $57.2 million during Q1 2021.
  • For the 5-year period, Amicus Therapeutics' Accumulated Expenses averaged around $114.5 million, with its median value being $124.9 million (2023).
  • Its Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 1913.28% in 2021, then soared by 7285.0% in 2022.
  • Over the past 5 years, Amicus Therapeutics' Accumulated Expenses (Quarter) stood at $98.2 million in 2021, then dropped by 4.6% to $93.6 million in 2022, then surged by 54.05% to $144.2 million in 2023, then fell by 11.75% to $127.3 million in 2024, then surged by 34.46% to $171.2 million in 2025.
  • Its Accumulated Expenses was $171.2 million in Q3 2025, compared to $145.1 million in Q2 2025 and $129.9 million in Q1 2025.